February Table of Contents

External Link - article-85018.pdf

Articles in this issue

over 22 years ago

Article

Upping the Ante

over 22 years ago

Article

Knowing When to Pull the Plug On Your Experimental Drug

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

Pharmaceutical Executive Daily: Ipsen Enters Merger Agreement to Acquire Kartos Therapeutics

ByNicholas Jacobus

June 29th 2026

Pharma M&A Roundup: Ipsen to Acquire Kartos Therapeutics, Zymeworks to Acquire Theravance Biopharma

ByNicholas Jacobus

June 29th 2026

Why ‘Fully Staffed’ Field Teams Still Miss Revenue Targets—and How Pharma Can Fix It

ByKrista Pinto

June 29th 2026

EMA’s CHMP Recommends Eli Lilly’s Jaypirca for Approval

ByMike Hollan

June 26th 2026

The New Healthy Aging Imperative and What It Means for Pharma

ByKirsten Whipple

June 26th 2026

February Table of Contents

Articles in this issue

Related Content

Pharmaceutical Executive Daily: Ipsen Enters Merger Agreement to Acquire Kartos Therapeutics

Pharma M&A Roundup: Ipsen to Acquire Kartos Therapeutics, Zymeworks to Acquire Theravance Biopharma

Why ‘Fully Staffed’ Field Teams Still Miss Revenue Targets—and How Pharma Can Fix It

EMA’s CHMP Recommends Eli Lilly’s Jaypirca for Approval

The New Healthy Aging Imperative and What It Means for Pharma

Trending on PharmExec

Why ‘Fully Staffed’ Field Teams Still Miss Revenue Targets—and How Pharma Can Fix It

Pharma M&A Roundup: Ipsen to Acquire Kartos Therapeutics, Zymeworks to Acquire Theravance Biopharma

The New Healthy Aging Imperative and What It Means for Pharma

EMA’s CHMP Recommends Eli Lilly’s Jaypirca for Approval

Reading Between the Lines: Closing the T1D Misdiagnosis Gap